Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy

Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudyImpact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy, Published online: 08 March 2018; doi:10.1038/s41397-018-0018-4Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy

Source: The Pharmacogenomics Journal - March 8, 2018 Category: Drugs & Pharmacology Authors: Yu Wu Yilun Zhou Yuesong Pan Xingquan Zhao Liping Liu David Wang Chunxue Wang Hao Li S. Claiborne Johnston Xia Meng Yilong Wang Yongjun Wang Source Type: research